Tumormarkører ved epitelial ovariecancer

Morten H Sparholt; Estrid Høgdall; Claus K Høgdall; Morten H Sparholt; Estrid Høgdall; Claus K Høgdall

Tumormarkører ved epitelial ovariecancer

Morten H Sparholt, Estrid Høgdall, Claus K Høgdall, Morten H Sparholt, Estrid Høgdall, Claus K Høgdall

Det Sundhedsvidenskabelige Fakultet

2 Citationer (Scopus)

Abstract

In October 2007, the Danish government and regions made an agreement comprising acute treatment of ovarian cancer (OC) patients. The acute OC-package includes the tumour marker cancer antigen 125 (CA125) as an essential factor. This marker is yet not optimal due to too low sensitivity/specificity. There is therefore a need for new or supplementary markers to improve the treatment. As the agreement will be influencing all diagnostic procedures, there is, furthermore, a need for information about OC and tumor markers. In this article we review the literature and illustrate future challenges and opportunities in OC marker diagnostics.
Udgivelsesdato: 2009-Nov-23

Bidragets oversatte titel	Tumour markers in epithelial ovarian cancer
Originalsprog	Dansk
Tidsskrift	Ugeskrift for læger
Vol/bind	171
Udgave nummer	48
Sider (fra-til)	3505-9
Antal sider	5
ISSN	0041-5782
Status	Udgivet - 23 nov. 2009

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Citationsformater

@article{c8183fe068a111df928f000ea68e967b,

title = "Tumormark{\o}rer ved epitelial ovariecancer",

abstract = "In October 2007, the Danish government and regions made an agreement comprising acute treatment of ovarian cancer (OC) patients. The acute OC-package includes the tumour marker cancer antigen 125 (CA125) as an essential factor. This marker is yet not optimal due to too low sensitivity/specificity. There is therefore a need for new or supplementary markers to improve the treatment. As the agreement will be influencing all diagnostic procedures, there is, furthermore, a need for information about OC and tumor markers. In this article we review the literature and illustrate future challenges and opportunities in OC marker diagnostics. Udgivelsesdato: 2009-Nov-23",

author = "Sparholt, {Morten H} and Estrid H{\o}gdall and H{\o}gdall, {Claus K} and Sparholt, {Morten H} and Estrid H{\o}gdall and H{\o}gdall, {Claus K}",

note = "Keywords: CA-125 Antigen; Chemotherapy, Adjuvant; Female; Genetic Predisposition to Disease; Humans; Individualized Medicine; Mass Screening; Ovarian Neoplasms; Sensitivity and Specificity; Tumor Markers, Biological",

year = "2009",

month = nov,

day = "23",

language = "Dansk",

volume = "171",

pages = "3505--9",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "48",

}

TY - JOUR

T1 - Tumormarkører ved epitelial ovariecancer

AU - Sparholt, Morten H

AU - Høgdall, Estrid

AU - Høgdall, Claus K

AU - Sparholt, Morten H

AU - Høgdall, Estrid

AU - Høgdall, Claus K

N1 - Keywords: CA-125 Antigen; Chemotherapy, Adjuvant; Female; Genetic Predisposition to Disease; Humans; Individualized Medicine; Mass Screening; Ovarian Neoplasms; Sensitivity and Specificity; Tumor Markers, Biological

PY - 2009/11/23

Y1 - 2009/11/23

N2 - In October 2007, the Danish government and regions made an agreement comprising acute treatment of ovarian cancer (OC) patients. The acute OC-package includes the tumour marker cancer antigen 125 (CA125) as an essential factor. This marker is yet not optimal due to too low sensitivity/specificity. There is therefore a need for new or supplementary markers to improve the treatment. As the agreement will be influencing all diagnostic procedures, there is, furthermore, a need for information about OC and tumor markers. In this article we review the literature and illustrate future challenges and opportunities in OC marker diagnostics. Udgivelsesdato: 2009-Nov-23

AB - In October 2007, the Danish government and regions made an agreement comprising acute treatment of ovarian cancer (OC) patients. The acute OC-package includes the tumour marker cancer antigen 125 (CA125) as an essential factor. This marker is yet not optimal due to too low sensitivity/specificity. There is therefore a need for new or supplementary markers to improve the treatment. As the agreement will be influencing all diagnostic procedures, there is, furthermore, a need for information about OC and tumor markers. In this article we review the literature and illustrate future challenges and opportunities in OC marker diagnostics. Udgivelsesdato: 2009-Nov-23

M3 - Tidsskriftartikel

SN - 0041-5782

VL - 171

SP - 3505

EP - 3509

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 48

ER -

Tumormarkører ved epitelial ovariecancer

Abstract

FN’s Verdensmål

Fingeraftryk

Citationsformater